Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Euronext Alternext  >  Neovacs    ALNEV   FR0004032746

NEOVACS (ALNEV)

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Euronext Alternext
02/20/2017 02/21/2017 02/22/2017 02/23/2017 02/24/2017 Date
0.83(c) 0.97(c) 0.93(c) 0.94(c) 0.95(c) Last
163 199 18 593 588 3 057 733 1 121 177 1 087 357 Volume
-1.19% +16.87% -4.12% +1.08% +1.06% Change
More quotes
Financials (€)
Sales 2016 0,61 M
EBIT 2016 -12,8 M
Net income 2016 -10,9 M
Debt 2016 1,47 M
Yield 2016 -
Sales 2017 4,51 M
EBIT 2017 -11,5 M
Net income 2017 -11,1 M
Debt 2017 10,0 M
Yield 2017 -
P/E ratio 2016 -
P/E ratio 2017
EV / Sales2016 68,9x
EV / Sales2017 11,2x
Capitalization 40,4 M
More Financials
Company
Neovacs SA is a biotechnology company which engages in the development of active immunotherapies for treating auto-immune, inflammatory, and cancerous diseases.It focuses on the development of Tumor Necrosis Factor-Kinoid for treating Crohn's disease and rheumatoid polyarthritis, and... 
More about the company
Surperformance© ratings of Neovacs
Trading Rating : Investor Rating :
More Ratings
Latest news on NEOVACS
02/22 NEOVACS : and BioSense Sign Option Agreement Worth Up to 65 Million Plus Royalti..
02/21 NEOVACS : AND BIOSENSE SIGN OPTION AGREEMENT WORTH UP TO €65 MILLION PLUS ROYALT..
02/21 NEOVACS : AND BIOSENSE SIGN OPTION AGREEMENT WORTH UP TO €65 MILLION PLUS ROYALT..
02/16 NEOVACS : Stellar Biotechnologies Congratulates Partner's Decision to Extend Dru..
02/10 NEOVACS : Issued New Broad Patent in China for IFN Kinoid
02/10 NEOVACS : issued new broad patent in China for IFNalpha Kinoid
02/09 NEOVACS : issued new broad patent in China for IFNalpha Kinoid
02/06 NEOVACS : 2017 Financial Calendar
01/27 NEOVACS : Reports First Positive Immunogenicity Results for IFN Kinoid in Model ..
01/25 NEOVACS : REPORTS FIRST POSITIVE IMMUNOGENICITY RESULTS FOR IFNa KINOID IN MODEL..
More news
Sector news : Biotechnology & Medical Research - NEC
02/22 Genmab and J&J's cancer drug set for blockbuster sales this year
02/21 Icahn buys Bristol-Myers shares, adding to activist pressure
02/21DJBristol-Myers Expands Board, Boosts Buybacks Amid Activist Pressure
02/16 How Sanofi lost out to J&J in $30 billion battle for Actelion
02/14 Gilead challenges GSK with strong HIV drug data
More sector news : Biotechnology & Medical Research - NEC
Latest Tweets
02/23Retail investors cash in on Neovacs $65M lupus pact in China; deal includes d.. 
02/21BRIEF-Neovacs and Biosense sign option agreement worth up to €65 million plus.. 
02/06$SBOT: Stellar Biotechnologies issues a statement congratulating Neovacs S.A... 
01/29Week-end #Biotech #Medtech : Neovacs, Sensorion, I.Ceram, Biocorp, TXCell, CR..
3
01/25Neovacs Reports First Positive Immunogenicity Results for IFNα Kino.. 
More tweets
Qtime:11
Advertisement
Chart NEOVACS
Duration : Period :
Neovacs Technical Analysis Chart | ALNEV | FR0004032746 | 4-Traders
Full-screen chart
Technical analysis trends NEOVACS
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 4
Average target price 2,29 €
Spread / Average Target 144%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Miguel Sieler Chief Executive Officer & Director
Jean-Jacques Bertrand Chairman
Baptiste Pourtout Head-Finance
Géraldine Grouard-Vogel Chief Scientific Officer
Thérèse Croughs Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NEOVACS19.75%43
INCYTE CORPORATION21.03%23 098
QUINTILES IMS HOLDINGS..1.71%18 414
CELLTRION, INC.--.--%11 010
LONZA GROUP AG2.67%10 420
SEATTLE GENETICS, INC.22.38%8 928
More Results